<code id='C44412B637'></code><style id='C44412B637'></style>
    • <acronym id='C44412B637'></acronym>
      <center id='C44412B637'><center id='C44412B637'><tfoot id='C44412B637'></tfoot></center><abbr id='C44412B637'><dir id='C44412B637'><tfoot id='C44412B637'></tfoot><noframes id='C44412B637'>

    • <optgroup id='C44412B637'><strike id='C44412B637'><sup id='C44412B637'></sup></strike><code id='C44412B637'></code></optgroup>
        1. <b id='C44412B637'><label id='C44412B637'><select id='C44412B637'><dt id='C44412B637'><span id='C44412B637'></span></dt></select></label></b><u id='C44412B637'></u>
          <i id='C44412B637'><strike id='C44412B637'><tt id='C44412B637'><pre id='C44412B637'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          focus

          author:explore    - browse:1694
          ASH19 CAR-T
          Victor Segura Ibarra and Rita Serda, Ph.D., NCI, NIH

          The Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.

          That sounds staggering to many patients — but it’s far less than analysts expected.

          advertisement

          The therapy, called a CAR-T, is made by harvesting patients’ white blood cells and rewiring them to home in on tumors. Novartis’s product is the first CAR-T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for certain aggressive blood cancers.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          leisure time